Key facts
- This page summarizes Laura Brege's Form 4 filing for Mirum Pharmaceuticals, Inc. (MIRM).
- 4 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 12 Sep 2025, 20:00.
Laura Brege - 11 Sep 2025 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)
- Reporting relationship
- Director
- Issuer ticker
- MIRM
- Reported as of
- 11 Sep 2025
- Net transaction value
- -$1,009,868
- SEC form
- 4
- Accepted by SEC
- 12 Sep 2025, 20:00:09 UTC
- Prior SEC filing
- 18 Jun 2025
- Next SEC filing
- 01 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Judit Ryvkin, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Laura Brege filed Form 4 for Mirum Pharmaceuticals, Inc. (MIRM) on 12 Sep 2025.
Change
- Previous filing in this sequence was filed on 18 Jun 2025.
- Current net transaction value: -$1,009,868.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001365619
Primary reporting owner
Brege Laura
- Relationship
- Director
- Address
- C/O MIRUM PHARMACEUTICALS, INC., 989 E HILLSDALE BLVD., SUITE 300, FOSTER CITY
- Signature
- /s/ Judit Ryvkin, Attorney-in-Fact
- Signature date
- 12 Sep 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MIRM
transaction
Common Stock
Options Exercise
- Transaction value
- $255,000
- Shares
- +17,000
- Change %
- +108%
- Price
- $15.00
- Shares after
- 32,703
- Date
- 11 Sep 2025
- Ownership
- Direct
MIRM
transaction
Common Stock
Sale
- Transaction value
- $1,152,939
- Shares
- -15,509
- Change %
- -47%
- Price
- $74.34
- Shares after
- 17,194
- Date
- 11 Sep 2025
- Ownership
- Direct
- Footnotes
- F1
MIRM
transaction
Common Stock
Sale
- Transaction value
- $111,929
- Shares
- -1,491
- Change %
- -8.7%
- Price
- $75.07
- Shares after
- 15,703
- Date
- 11 Sep 2025
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MIRM
transaction
Derivative
Stock Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -17,000
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 11 Sep 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 17,000
- Exercise price
- $15.00
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The weighted average sale price for the transaction reported was $74.34, and the range of prices were between $73.73 and $74.73. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Footnote F2
The weighted average sale price for the transaction reported was $75.07, and the range of prices were between $74.745 and $75.19. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Footnote F3
The stock option is fully vested.